COMPASS Pathways plc to participate in 20th Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

COMPASS Pathways plc (Nasdaq: CMPS) announced a corporate update presentation at the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 8:00 am ET. The update will be delivered by CEO George Goldsmith and President Lars Wilde, along with 1:1 investor meetings. A live audio webcast will be accessible via the COMPASS website, with a 30-day replay available afterward. COMPASS focuses on innovative mental health care solutions, particularly through its psilocybin therapy, COMP360, currently in phase IIb clinical trials for treatment-resistant depression.

London, UK, April 09, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that George Goldsmith, Chairman, CEO and Co‑founder, and Lars Wilde, President, Chief Business Officer, and Co‑founder, will present a corporate update at 8:00am ET on 15 April at the 20^th Annual Needham Virtual Healthcare Conference. Members of the COMPASS management team will also be holding 1:1 investor meetings.  

A live audio webcast of the presentation will be available on the "Events" page of the Investors section of the COMPASS website. A replay of the webcast will be available for 30 days following the event. For more information, please visit ir.compasspathways.com.

-Ends-

About COMPASS Pathways

COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, USA. Our vision is a world of mental wellbeing. www.compasspathways.com

 

Contacts:

 

Media: Tracy Cheung, tracy@compasspathways.com, +44 7966 309024
Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401-290-7324

 

 

Attachment

• CMPS Needham Conference Participation - 4.8.21

FAQ

What time is COMPASS Pathways' presentation at the Needham Virtual Healthcare Conference on April 15, 2021?

The presentation will take place at 8:00 am ET on April 15, 2021.

Who will present at the COMPASS Pathways corporate update on April 15, 2021?

The presentation will be delivered by George Goldsmith, CEO, and Lars Wilde, President.

How can I access the COMPASS Pathways conference presentation?

You can access the live audio webcast on the 'Events' page of the COMPASS website.

What is COMP360 and its significance for COMPASS Pathways?

COMP360 is a proprietary psilocybin therapy designed for treatment-resistant depression and has FDA Breakthrough Therapy designation.

What clinical trial is COMPASS Pathways currently conducting?

COMPASS is conducting a phase IIb clinical trial of psilocybin therapy for treatment-resistant depression across 22 sites in Europe and North America.